

Subt. For, PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Sheet 1 OF 2

Docket Number
47508-518
HYZ-030CPCN3

Application Number
09/777,526

Applicant
Agrawal, et al.

Filing Date
2/6/2001

Group Art Unit
1635

U.S. Patent Documents

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO94/23028	10/13/1994	WO				
	WO96/12497	5/2/1996	WO				
	WO97/11171	3/27/1997	WO				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

	A1	Agrawal; "In Vivo Pharmacokinetics of Oligonucleotides"; in <u>Applied Antisense Oligonucleotide Technology</u> (Stein and Krieg, Eds.), pp. 365-385 (1998)
	A2	Agrawal, "Preface", in <u>Methods in Molecular Medicine: Antisense Therapeutics</u> (Agrawal, Ed.); pp. v-vii (1996)
	A3	Agrawal, et al.; "Comparative Pharmacokinetics of Antisense Oligonucleotides"; in <u>Methods in Molecular Medicine: Antisense Therapeutics</u> (Agrawal, Ed.); pp. 247-270 (1996)
1	A4	Branch; "A Good Antisense Molecule is Hard to Find"; TIBS 23; pp. 45-50, February 1998
1	A5	Crooke; "Basic Principles of Antisense Therapeutics"; in <u>Antisense Research and Application</u> (Crooke, Ed.); pp. 1-50 (1998)
1	A6	Crystal; "Transfer of Genes to Humans: Early Lessons and Obstacles to Success"; Science; vol. 270, pp. 404-410 (1995)
	B1	Friedmann; "Overcoming the Obstacles"; Scientific American; pp. 96-101, June 1997

EXAMINER	DATE CONSIDERED
----------	-----------------


EXAMINER: Initial if citation is considered, whether or not citation is in conformance with if not conformance and not considered. Include copy with next communication to applicant.

RECEIVED
Drawn in through citation

BOSTON 1514336v1

OCT 10 2002

TECH CENTER 1600/2900



Sub. For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Sheet

2

OF

2

Docket Number
47508-518
HYZ-030CPCN3

Application Number
09/777,526

Applicant
Agrawal, et al.

Filing Date
2/6/2001

Group Art Unit
1635

	B2	Monia, et al.; "Antitumor Activity of a Phosphorothioate Antisense Oligodeoxynucleotide Targeted Against C-raf Kinase"; Nature Medicine; Vol. 2, No. 6, pp. 668-675, June 1996
	B3	Schofield et al.; "Non-viral Approaches to Gene Therapy"; British Medical Bulletin; Vol. 51, No. 1, pp. 56-71 (1995)
	B4	Verma, et al.; "Gene Therapy – Promises, Problems, and Prospects"; Nature; Vol. 389, pp. 239-242, September 1997
	B5	Vlassov, et al.; "In Vivo Pharmacokinetics of Oligonucleotides Following Administration by Different Routes"; in <u>Delivery Strategies for Antisense Oligonucleotide Therapeutics</u> (Akhtar, Ed.); pp. 71-83 (1995).
	B6	Vlassov, et al.; "Penetration of Oligonucleotides into Mouse Organism through Mucosa and Skin"; FEBS Letters; Vol. 327, No. 3, pp. 271-274; August 1993
	B7	
	B8	
	B9	
	B10	
	B11	
	B12	
	B13	
	B14	
	B15	
	C1	
	C2	
	C3	
	C4	
	C5	
	C6	
	C7	
	C8	
	C9	
	C10	
	C11	
	C12	
	C13	
	C14	
	C15	
	C16	
	C17	
	D1	
	D2	
	D3	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

BOSTON 1514336v1

RECEIVED

OCT 10 2002

TECH CENTER 1600/2900